Company profile for Kare Biosciences

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

KARE Biosciences is developing KAR101 (ramatroban) as a disease-modifying therapy for multiple indications, including COVID-19. KAR101 is a novel dual antagonist of thromboxane A2/TP and prostaglandin D2/DP2 receptors. Ramatroban has been used safely for over 20 years in Japan to treat allergic rhinitis and has a strong safety record. Recognizing its therapeutic potential, KARE Biosciences has launched the KAR series?dual rece...
KARE Biosciences is developing KAR101 (ramatroban) as a disease-modifying therapy for multiple indications, including COVID-19. KAR101 is a novel dual antagonist of thromboxane A2/TP and prostaglandin D2/DP2 receptors. Ramatroban has been used safely for over 20 years in Japan to treat allergic rhinitis and has a strong safety record. Recognizing its therapeutic potential, KARE Biosciences has launched the KAR series?dual receptor antagonists targeting a range of diseases driven by inflammation and immune dysregulation.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty